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Background: Human chorionic gonadotropin (HCG) has been used as a 
replacement for the mid-cycle luteinizing hormone (LH) surge for several years. The 
recent arrival of recombinant DNA technology has made recombinant HCG (rHCG) 
accessible. 
Objective: To assess efficacy of rHCG compared to urinary HCG (uHCG) for 
triggering of ovulation and induction of final oocyte maturation in assisted 
reproductive cycles. 
Materials and Methods: 200 patients who were candidate for ICSI were randomly 
divided in two groups. In group I (rHCG), patients received 250µg of rHCG for final 
oocyte maturation, and in group II (uHCG) the patients received 10000 IU of uHCG. 
Measured outcomes were number of retrieved oocyte and mature oocyte, maturation 
rate of oocyte, fertilization rate and clinical pregnancy rate. 
Results: The rates of oocyte maturity were similar in both groups. Fertilization rate 
was similar in two groups (58.58% in rHCG group versus 60.58% in uHCG group 
p=0.666). The clinical pregnancy rate per cycle was similar in both group 34.0% in 
rHCG group versus 39% in uHCG group (p=0.310). 
Conclusion: We demonstrated that rHCG is as effective as uHCG, when it is used 
for final oocyte maturation in ICSI cycles. The numbers of retrieved oocyte and 
maturation rates were similar in both groups; also fertilization and clinical 
pregnancy rates were similar. 
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he preovulatory surge of luteinizing 
hormone (LH) performs physiological 
stimulation for final oocyte maturation 
and causes ovulation (1-4). After LH surges 
the process of meiosis progress, the oocyte 
completes meiosis I and starts meiosis II, the 
oocyte and cumulus cells separates from the 
follicle wall and eventually lead to release of 
the oocyte-cumulus complex (5). 
The mature oocyte is then picked up by 
fimbrial end of fallopian tube (1). Throughout 
assisted reproduction cycles, premature LH 
surge affects cycle outcomes. Premature LH 
surge could lead to premature ovulation and 
as a result, interfere with oocyte collection 
during cycles. Premature luteinization also 
negatively affects egg quality and 
synchronization between embryos and 
endometrium. For prevention of LH surge 
GnRH agonist or antagonist is used in 
combination with gonadotropin in ART cycles 
(6, 7).  
Therefore, LH surge is needed to create by 
consumption of exogenous hormones for final 
oocyte maturation and ovulation induction in 
ART (8). Human chorionic gonadotropin 
(HCG) is produced by the trophoblasts from 
the early days of implantation which supports 
the corpus luteum and feto-placental 
communication (9-11).  
HCG is a glycoprotein and structurally is 
similar to LH; both hormones have similar 
effect and bind to the same receptors. UHCG 
is collected from urine of pregnant women, 
which has been clinically used for triggering of 
ovulation and luteinization in anovulatory 
women (12). For at least 3 recent decades, 
uHCG has also been used for final oocyte 
maturation and luteal phase support (11, 13, 
14).  
However, consumption of UHCG is 
associated with a number of disadvantages, 
T 
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the source of drug is urine of pregnant women 
and it is an uncontrolled source. Therefore 
purity of uHCG could differ from batch-to-
batch and eventually lead to variation in 
activity and result (15). 
On the other hand, rHCG is derived from 
genetically engineered Chinese hamster ovary 
cells by recombinant DNA technology. The 
high purity of this product makes the drug 
suitable for subcutaneous injection, and is 
self-injection (16). The aim of study was to 
assess the efficacy of rHCG compared to 
uHCG for triggering the ovulation and 
induction of final oocyte maturation in assisted 
reproductive cycles.  
 
Materials and methods 
 
This study was conducted at Yazd 
Research and Clinical Center for Infertility, 
affiliated to Shahid Sadoughi University of 
Medical Sciences from January 2009 to July 
2010. The study was approved by Ethic 
Committee, and written informed consent was 
taken from all participants. 200 Women with 
regular menstrual cycles, age <38 years old, 
FSH <10IU/L and BMI <30kg/m2 were 
included in this study.  
The exclusion criteria was history of 
metabolic or endocrine disorder, history of 
pelvic surgery and severe male factor infertility 
which was defined as severe oligospermia 
(<5million sperm/ml), asthenospermia (5% 
progressive motility), or teratospermia (4% 
normal forms by strict criteria). The study was 
a prospective randomized study and allocation 
of the patients into two groups was done 
alongside by using packets which included 
computerized randomization (figure 1). 
Pituitary desensitization was done for both 
groups by administration of Decapeptyl 
(Decapeptyl® 0.1 mg, Ferring, Germany) 0.1 
mg per day subcutaneously from previous 
mid-luteal phase, and was continued until the 
day of HCG injection. Pituitary desensitization 
confirmed by sonography in second day of 
cycle.  
If endometrial thickness was less than 5 
mm in diameter and ovarian cyst more than 
10 mm in diameter was not seen, then ovarian 
stimulation was started from second day of 
menstrual cycle by administration of (150 IU) 
of human recombinant follicle-stimulating 
Hormone (Gonal-F, Serono, Aubnne, 
Switzerland). It was injected subcutaneously 
and dose of Gonal-F was adjusted according 
to patients’ response then continued until the 
day of HCG injection. Monitoring of cycle was 
done by serial vaginal ultrasonography and 
measurement of serum estradiol level.  
When at least two dominant follicles 
reached to 18mm in mean diameter or two 
follicles with mean diameter larger than 16 
mm diameter and one by mean diameter >18 
mm was observed in vaginal sonography, the 
patients were divided into two groups. In 
group I (rHCG), 100 patients received a single 
subcutaneous injection of 250 µg rHCG 
(Ovidrel). In group II (uHCG), 100 patients 
received a single intramuscular injection of 
10000 IU urinary HCG (pregnyl, ® organon, 
oss, Netherlands). In both group oocyte 
retrieval was done 34-36 hours after HCG 
injection by using a 17 gauge needle under 
ultrasound guidance through the vaginal rout.  
The numbers of retrieved oocyte were 
recorded. Approximately two hours after 
retrieval cumulus and corona radiate cell were 
removed gently under an inverted microscope. 
Metaphase II oocytes (mature oocytes) were 
characterized by the presence of first polar 
body, metaphase I oocytes were 
characterized by absence of both germinal 
vesicle and first polar body and prophase I 
oocytes were characterized by its distinct 
germinal vesicle. Intra cytoplasmic injection 
(ICSI) was done for all cycles and only mature 
oocytes were injected.  
About 18 hours after microinjection, 
oocytes were evaluated for fertilization 
presence of pronuclear and two polar bodies 
were considered as normal fertilized oocyte. 
Embryos were transferred 2 days after oocyte 
retrieval. Good quality embryos were 
transferred in both groups by using Labotect 
catheter (Labtect, Gottingen, Germany). 
Luteal phase support was done by intra 
muscular injection of 100 mg progesterone 
(progesterone, Aburaihan CO, Tehran, Iran), 
starting from day of oocyte retrieval and 
continued until observation of fetal heart 
activity by vaginal sonography.  
If estradiol level reached greater than 
3000pg/ml and /or more than 15 follicles with 
greater than 14 mm in diameter was observed 
in each ovary by vaginal sonography, the 
patient was considered at risk of ovarian 
hyper stimulation syndrome (OHSS). The 
primary outcome was the numbers of mature 
oocyte, maturation rates of oocyte was 
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defined as the numbers of mature oocyte 
retrieved per numbers of retrieved oocyte. 
Chemical pregnancy was defined as serum 
βHCG >50IU/L measured 2 weeks after 
embryo transfer. Clinical pregnancy was 
defined as observation of fetal heart activity by 
ultrasonography 3 weeks after positive βHCG.  
 
Statistical Analysis 
Statistical analysis was carried out using 
the statistical package for the social science 
(SPSS version 15.0 for windows, Chicago, IL). 
Both t-test and chi-square test were used to 
detect significant differences (p<0.05) of the 




Basic characteristics of patients regarding 
female age, duration of infertility, basal FSH 
and etiology of infertility was statistically 
similar in both groups (Table I). The cycle’s 
characteristics and ART outcomes is 
presented in table II. Duration of stimulation, 
dose of FSH (IU) used, numbers of follicle >14 
mm in diameter, numbers of retrieved oocyte 
and mature oocyte, maturation rate of oocyte 
and numbers of embryos transferred were 
statistically similar in both groups.  
Fertilization rate was similar in two groups 
(58.58% in rhCG group versus 60.58% in 
uhCG group; p=0.666). Clinical pregnancy 
rate per cycle was similar in both groups 
(34.0% in rhCG group versus 39% in uhCG 
group; p=0.310). Embryo transfer was 
cancelled in 7 cycles in rHCG group and 8 
cycles in uHCG group due to risk of mild to 
moderate OHSS (p=1.000). No case of severe 
OHSS was seen. However none of these 





Table I. Basic characteristic of patients undergoing ICSI 
Variable rHCG (group I) (n=100) uHCG (group II) (n=100) p-value 
Age(year) 
 
29.63 ± 4.85 29.30 ± 4.89 0.637 
Duration of infertility (years) 
 
9.01 ± 6.66 8.98 ± 7.45 0.988 
Basal FSH(IUI/L) 
 
7.65 ± 3.62 6.75 ± 3.35 0.125 
Infertility causes 0.382 
 
Male factor (%) 
 
41 (41) 43 (43) 
 
 
Tubal factor (%) 
 
6 (6) 11 (11) 
 
Unexplained factor (%)  
 
25 (25) 20 (20) 
 
Mild endometriosis (%) 
 




13 (13) 6 (6) 
 
Ovarian factor (%) 
 
10 (10) 16 (16) 





Table II. Cycle characteristic and ICSI outcome 
Variable rHCG (group I) (n=100) uHCG (group II) (n=100) p-value 
Duration of stimulation(d) 
 
11.24 ± 2.26 11.33 ± 1.90 0.753 
Dose of FSH used (IU) 
 
2028 ± 680 2154 ± 894 0.267 
No of follicle >14 mm 
 
12.34 ± 12.5 11.81 ± 671 0.716 
No. of retrieved oocytes  
 
9.75 ± 6.65 9.64 ± 7.29 0.920 
No. of mature oocytes 
 
8.34 ± 5.27 8.27 ± 6.44 0.935 
Maturation rate of oocytes 
 
87.99% 86.25% 0.543 
No. of transferred embryos 
 
2.30 ± 0.90 2.09 ± 1.15 0.194 
Fertilization rates 
 
58.58% 60.58% 0.666 
Clinical pregnancy rates 
 
34% 39% 0.310 
Abortion (%) 
 
4 (11.76%) 5 (12.8%) 1.000 
Mild to moderate OHSS (%) 
 
7 (7%) 8 (8%) 1.000 
Endometrial thickness 
 
9.49 ± 1.63 9.82 ± 1.59 0.221 
Parameters expressed as mean ± SD or percentages, as appropriate. 
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Our study was done for evaluation of 
efficacy of rHCG compared to uHCG. 
According to our findings; we demonstrated 
that rHCG is as effective as uHCG, when it is 
used for final oocyte maturation in ICSI cycles. 
The numbers of retrieved oocyte and 
maturation rates were similar in both groups; 
also fertilization and clinical pregnancy rates 
were similar. In contrast to our study, Geneva 
compared rHCG and uHCG, and 
demonstrated that despite administration of 
similar doses, rHCG was associated with 
higher numbers of mature oocytes per cycles. 
He suggested that HCG degenerated 
products in the urinary preparation have slight 
interference with the active HCG molecules 
and consequently with the HCG induced 
oocyte maturation (3, 11).  
In consistent with Geneva, Farag et al 
analyzed the effect of rHCG on oocyte nuclear 
and cytoplasmic maturity compared to uHCG 
when it used for inducing ovulation. They 
showed that rHCG resulted in a statistically 
higher rates of mature oocytes regarding 
nuclear and cytoplasmic maturity (1). Similar 
to our study, Driscoll et al in a prospective and 
randomized study compared rHCG and uHCG 
for inducing oocyte maturation and follicular 
luteinization in ovarian stimulation. Primary 
outcome including number of retrieved 
oocytes per follicles, the number of mature 
oocytes and fertilization rate were similar in 
both groups.  
On the other hand, they showed that 
progesterone concentration 6-7 days after 
HCG administration was greater in the rHCG 
group than in uhCG group. Therefore they 
suggested that whether this would allow a 
more favorable luteal environment for 
implantation will require further investigation 
(17). Meike et al also compared clinical 
outcomes of rHCG and uHCG in fresh non 
donor cycles. They showed that rate of mature 
oocytes, fertilization and clinical pregnancy 
were similar in two groups (18).  
Assessed for eligibility (n=200) 
Excluded (n= 0) 
 Not meeting inclusion criteria (n=0) 
 Declined to participate (n=0) 
 Other reasons (n=0) 
Analysed (n= 100) 
 Excluded from analysis (give reasons) (n= 0) 
Lost to follow-up (give reasons) (n= 0) 
 Discontinued intervention (give reasons) 
(n= 0) 
Allocated to intervention (n= 100) 
 Received allocated intervention (n=100) 
 Did not receive allocated intervention (give 
reasons) (n= 0) 
Lost to follow-up (give reasons) (n= 0) 
 Discontinued intervention (give reasons) 
(n=0) 
Allocated to intervention (n= 100) 
 Received allocated intervention (n= 100) 
 Did not receive allocated intervention (give 
reasons) (n= 0) 
Analysed (n=100) 
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AL-Inany et al in a systemic review 
assessed the safety and efficacy of 
subcutaneous rHCG. They evaluated 4 trials 
including 747 participants, and concluded that 
there were no statistically significant 
differences between groups regarding 
ongoing and delivered pregnancy rate per 
women (24.1% in the rHCG group and 22.8% 
in the uHCG group).  
They reported the rate of severe OHSS 
3.3% in the rHCG group versus 1.9% in uHCG 
group (19), similar to this finding ,we showed 
that risk of OHSS was the same in two group. 
Our data demonstrated that injection of 250µg 
of rHCG (Ovidrel) is equal to an intramuscular 
injection of 10000 IU of uHCG in inducing final 
follicular maturation in ICSI cycles. We would, 
therefore, recommend that people under 
treatment for problems created by opium 
during the withdrawal process receive special 
attention to testicular atrophy through 
consultation with an urologist alongside 
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